SCHEMBL24784637

SCHEMBL24784637

COc1cc(C#N)cc(-c2ncc(CO)cn2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 2/20 0.44
▸ KDM1A O60341 2/20 0.44
▸ LRRK2 Q5S007 1/20 0.40
▸ PGR P06401 1/20 0.38
▸ CYP1A1 P04798 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2E1 P05181 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2C8 P10632 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ CYP2A6 P11509 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP4B1 P13584 1/20 0.37
▸ CYP2B6 P20813 1/20 0.37
▸ CYP3A5 P20815 1/20 0.37
▸ CYP2A7 P20853 1/20 0.37
▸ CYP3A7 P24462 1/20 0.37
▸ CYP2F1 P24903 1/20 0.37
▸ CYP2C18 P33260 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30018769 1.00 GRM5 (0.44) GRM5KDM1ALRRK2PGRCYP1A1
SCHEMBL24784608 0.78 KDM1A (0.40) KDM1ALRRK2PGRCYP1A1CYP1A2
SCHEMBL4695771 0.77 ALDH1A1 (0.41) —
SCHEMBL24785094 0.74 CLK4 (0.63) CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL24784552 0.72 CLK4 (0.56) —
SCHEMBL202404 0.71 ALDH1A1 (0.61) GRM5KDM1APGRCYP1A1CYP1A2
SCHEMBL31128598 0.70 NOTUM (0.46) GRM5KDM1ALRRK2
SCHEMBL509576 0.69 ALDH1A1 (0.58) GRM5KDM1APGRCYP1A1CYP1A2
SCHEMBL16951966 0.68 PDE4A (0.38) —
SCHEMBL20282676 0.68 ALDH1A1 (0.46) GRM5KDM1ALRRK2PGRCYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022257960-A1 BICYCLIC COMPOUND FOR THE TREATMENT OF EP2 AND EP4 RECEPTOR-MEDIATED DISEASES 武汉人福创新药物研发中心有限公司 2022-12-15 — — WO disclosed
Send feedback